TY - JOUR T1 - [Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer – Basal Cell Carcinoma or Squamous Cell Carcinoma – Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study JO - Actas Dermo-Sifiliográficas T2 - AU - Miñano Medrano,R. AU - López Estebaranz,J.L. AU - Sanmartin-Jiménez,O. AU - Garcés,J.R. AU - Rodríguez-Prieto,M.A. AU - Vilarrasa-Rull,E. AU - de Eusebio-Murillo,E. AU - Escutia-Muñoz,B. AU - Flórez-Menéndez,Á. AU - Artola-Igarza,J.L. AU - Alfaro-Rubio,A. AU - Redondo,P. AU - Delgado-Jiménez,Y. AU - Sánchez-Schmidt,J.M. AU - Allende-Markixana,I. AU - Alonso-Pacheco,M.L. AU - García-Bracamonte,B. AU - de la Cueva-Dobao,P. AU - Navarro-Tejedor,R. AU - Ciudad-Blanco,C. AU - Carnero-González,L. AU - Vázquez-Veiga,H. AU - Cano-Martínez,N. AU - Ruiz-Salas,V. AU - Sánchez-Sambucety,P. AU - Botella-Estrada,R. AU - González-Sixto,B. AU - Martorell-Calatayud,A. AU - Gil,P. AU - Morales-Gordillo,V. AU - Toll-Abelló,A. AU - Ocerin-Guerra,I. AU - Mayor-Arenal,M. AU - Suárez-Fernández,R. AU - Sainz-Gaspar,L. AU - Descalzo,M.A. AU - García-Doval,I. SN - 00017310 M3 - 10.1016/j.ad.2022.01.035 DO - 10.1016/j.ad.2022.01.035 UR - https://www.actasdermo.org/es-translated-article-risk-second-skin-articulo-S0001731022002940 AB - ObjectivePatients with nonmelanoma skin cancer (NMSC)—ie, basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)—have an increased risk of developing a second skin cancer. The aim of this study was to describe the frequency, incidence per 1000 person-years, and predictors of a second skin cancer in a cohort of patients with NMSC treated with Mohs micrographic surgery (MMS). Material and methodsProspective study of a national cohort of patients with NMSC who underwent MMS at 22 Spanish hospitals between July 2013 and February 2020; case data were recorded in the REGESMOHS registry. The study variables included demographic characteristics, frequency and incidence per 1000 person-years of second skin cancers diagnosed during the study period, and risk factors identified using mixed-effects logistic regression. ResultsWe analyzed data for 4768 patients who underwent MMS; 4397 (92%) had BCC and 371 (8%) had SCC. Mean follow-up was 2.4 years. Overall, 1201 patients (25%) developed a second skin cancer during follow-up; 1013 of the tumors were BCCs (21%), 154 were SCCs (3%), and 20 were melanomas (0.4%). The incidence was 107 per 1000 person-years (95% CI, 101–113) for any cancer, 90 per 1000 person-years (95% CI, 85–96) for BCC, 14 (95% CI, 12–16) per 1000 person-years for SCC, and 2 (95% CI, 1–3) per 1000 person-years for melanoma. More men than women developed a subsequent skin cancer (738 [61%] vs 463 [39%]). The main risk factors were a history of multiple tumors before diagnosis (relative risk [RR], 4.6; 95% CI, 2.9–7.1), immunosuppression (RR, 2.1; 95% CI, 1.4–3.1), and male sex (RR, 1.6; 95% CI, 1.4–1.9). ConclusionPatients have an increased risk of developing a second tumor after MMS treatment of NMSC. Risk factors are a history of multiple tumors at diagnosis, immunosuppression, and male sex. ER -